Cargando…
Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare
PURPOSE: Beginning in July of 2018, the FDA issued a voluntary recall regarding the presence of a contaminant found in the manufacturing of valsartan. What would ensue has become a largely unprecedented sequence of alarming events since the FDA began reporting public recalls, withdrawals and safety...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171054/ https://www.ncbi.nlm.nih.gov/pubmed/32318933 http://dx.doi.org/10.1007/s10557-020-06976-0 |